• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MERZ ULTHERAPY; FOCUSED ULTRASOUND FOR TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MERZ ULTHERAPY; FOCUSED ULTRASOUND FOR TISSUE Back to Search Results
Health Effect - Clinical Codes Hair Loss (1877); Neurological Deficit/Dysfunction (1982); Seizures (2063); Tissue Damage (2104); Loss of Vision (2139); Burn, Thermal (2530); Electric Shock (2554)
Type of Reportable Event Serious Injury
Event or Problem Description
Several months after ultherapy at (b)(6), i went into a seizure and my face went into tetanus and ripped off the skeleton.I was burned alive and self-electrocuting, as ultherapy uses an electric current and 170 degrees and disrupted the body's natural electricity.I burned alive for almost 2 years.I would have been dead of a stroke.Vision loss, fat, tissue loss, eyelids lashes gone, neurological issues, seizures, cns damage, 4th degree electrical burns.Unable to have children.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ULTHERAPY
Common Device Name
FOCUSED ULTRASOUND FOR TISSUE
Manufacturer (Section D)
MERZ
MDR Report Key6222296
Report NumberMW5067033
Device Sequence Number13088956
Product Code OHV
Initial Reporter StateFL
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Voluntary
Initial Reporter Occupation Patient
Type of Report Initial
Report Date (Section B) 01/03/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Operator of Device Health Professional
Was Device Available for Evaluation? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer Not provided
Initial Report FDA Received Date01/03/2017
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
OTC MEDS: BENADRYL.; RX MEDS: GABAPEPTIN FOR SEIZURES AND NERVE PAIN.
Outcome Attributed to Adverse Event Life Threatening;
Patient Age43 YR
Patient Weight50
-
-